Outlook Therapeutics, Inc.
OTLK
$0.70
-$0.02-2.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 110.55% | -1,215.69% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 110.55% | -1,215.69% | |||
| Cost of Revenue | 404.39% | 100.15% | |||
| Gross Profit | 98.23% | -106.13% | |||
| SG&A Expenses | 10.36% | -16.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.30% | -28.72% | |||
| Operating Income | -4.03% | 22.12% | |||
| Income Before Tax | 80.69% | -55.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 80.69% | -73.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 80.69% | -73.46% | |||
| EBIT | -4.03% | 22.12% | |||
| EBITDA | -4.03% | 22.16% | |||
| EPS Basic | 85.80% | -35.96% | |||
| Normalized Basic EPS | 67.41% | 11.86% | |||
| EPS Diluted | 85.80% | -35.29% | |||
| Normalized Diluted EPS | 67.41% | 11.86% | |||
| Average Basic Shares Outstanding | 35.93% | 27.57% | |||
| Average Diluted Shares Outstanding | 35.93% | 27.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||